NCT01290419View on ClinicalTrials.gov

Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSV-F Particle Vaccine

Dose 1 + adjuvant / dose; Day 0 and Day 30

BIOLOGICAL

RSV-F Particle Vaccine

Dose 2 + adjuvant / dose; Day 0 and Day 30

BIOLOGICAL

RSV-F Particle Vaccine

Dose 3 + adjuvant / dose; Day 0 and Day 30

BIOLOGICAL

RSV-F Particle Vaccine

Dose 3 / dose; Day 0 and Day 30

BIOLOGICAL

Placebo

Placebo; Day 0 and Day 30

BIOLOGICAL

RSV-F Particle Vaccine

Dose 4 / dose; Day 0 and Day 30

BIOLOGICAL

RSV-F Particle Vaccine

Dose 4 + adjuvant / dose; Day 0 and Day 30

Trial Locations (1)

78209

Healthcare Discoveries d/b/a ICON Development Solutions, San Antonio

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
lead

Novavax

INDUSTRY